[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mace\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mace":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,97,132,166,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100589242","tezspire-cardiac-events-pass-100589242",false,"NCT06951867","Tezspire Cardiac Events PASS","An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients With Severe Asthma Taking Tezepelumab","TRESPASS","Inclusion Criteria:\n\n* patients with a diagnosis of asthma receiving tezepelumab or high-intensity SOC treatment for severe asthma at any point during the study inclusion period.\n\nExclusion Criteria for both exposed and unexposed groups include:\n\n* \\\u003C12 months of data availability prior to index date,\n* age \\\u003C12 years at index date,\n* history of congenital heart disease or heart transplant outcome-specific exclusion criterion applied for each objective will include the presence of non-fatal myocardial infarction or stroke and the specific outcome of interest in the 180 days prior to index date\n* for comparative analysis, an additional exclusion criterion will be considered, i.e. exposure to non-tezepelumab biologics on index date or within the 5-half-life clearance period of the biologic\n* matching criteria (including, among other variables, the type and duration of SOC exposure in the 12 months before index date and propensity score \\[PS\\] matching) will be applied to ensure exposed and unexposed patients' comparability","ALL","12 Years","130 Years",{"count":21,"type":22},16640,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.",[26,27],"Cardiovascular Events","MACE",[29,30,31,32,33,34,35,36,37],"post Marketing Requirements (PMR) study","cardiovascular events","non-fatal myocardial infarction","non-fatal stroke","cardiovascular death","arrythmias","coronary artery disease","heart failure","myocardial disorders","RECRUITING","2026-06-03",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":42},"2025-09-15",{"date":46,"type":22},"2029-05-31",{"name":48,"class":49},"AstraZeneca","INDUSTRY",4,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":64,"studyType":23,"phases":4,"briefSummary":65,"conditions":66,"keywords":75,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100626909","thromboembolic-risk-associated-to-high-atrial-fibrillation-risk-100626909","NCT07441759","throMboembolic Risk Associated To High atrIal Fibrillation riSk","Economic, Clinical, and Societal Impact of Early Thromboembolic -Risk Detection in High-Risk Atrial Fibrillation: A Model -Based Evaluation of the MATHIAS Strategy.","MATHIAS","Inclusion Criteria (PREFATE study): assessed at baseline\n\n* Adults aged 65-95 years without prior AF and at High risk of AF, according to the risk score validated in the AFRICAT (Atrial Fibrilation Research in CATalonia) study. This scale considers the following variables for risk calculation: sex, age, weight, cardiac rate and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65-74, female) score.\n* with active records in the HCC3\u002FCMBD systems\n* CHA2DS2-VASc score≥2.\n* Ability to use a smart phone (or at least the caregiver).\n\nExclusion Criteria: Patients with the following conditions will be excluded (exclusion criteria):\n\n* Previous diagnosis of AF.\n* Previous diagnosis of stroke.\n* Severe cognitive impairment, with a score on the Global Deterioration Scale (GDS)≥3.\n* Severe functional impairment, with a Barthel score ≤60, or modified Rankin score≥4.\n* Active anticoagulant treatment at the inclusion.\n* Vital prognosis less than 1 year.\n* Pacemaker carriers.",true,"65 Years","95 Years",{"count":63,"type":22},1000,"2 Years","Cardiovascular diseases are the leading cause of mortality from treatable conditions in the European Union and the second from preventable causes, with a standardized mortality rate of 257.8 deaths per 100,000 inhabitants. In 2022, more than 1.11 million deaths in individuals under 75 years could have been avoided. Atrial fibrillation (AF) and major adverse cardiovascular events (MACE) are highly prevalent in the elderly and generate substantial healthcare costs. AF significantly increases the risk of MACE and is projected to rise markedly in the coming decades.\n\nIn Europe, AF prevalence is expected to increase 2.5-fold over the next 50 years, with a lifetime risk of 1 in 3-5 individuals after age 55. AF-related strokes are projected to increase by 34%, and ischemic strokes in individuals over 80 are expected to triple between 2016 and 2060. Additionally, a 27% increase is anticipated among stroke survivors who subsequently develop AF or related conditions. AF substantially impacts morbidity, mortality, and disease progression, and early detection and treatment are crucial to prevent severe outcomes.\n\nEuropean action plans (2018-2030) and the 2024 ESC\u002FESO guidelines emphasize early detection and management of AF in primary care. Although several AF prediction models exist, their integration into clinical practice remains challenging. AF represents a clinical continuum, with thrombotic risk present even before arrhythmia onset. High-risk patients for AF also show a high incidence of MACE, defined as a composite of myocardial infarction, stroke, systemic embolic events, and cardiovascular death.\n\nThe proposed strategy involves developing and clinically validating an Artificial Intelligence (AI) model to improve early thrombotic risk prediction in patients at high risk of AF, using MACE as the primary outcome. This model aims to outperform the traditional CHA₂DS₂-VASc score by incorporating both classical and emerging clinical factors. The estimated timeline from clinical validation to commercialization is approximately 48 months.\n\nAI-based prediction is expected to enable personalized treatment, reduce the incidence of MACE, hospitalizations, and disability, and improve cost-effectiveness, ultimately decreasing the social and economic burden of AF and stroke in Europe.",[27,67,68,69,70,71,72,73,74],"Atrial Fibrillation (AF)","Quality-adjusted Life-years","Electronic Health Records","Thromboembolic Risk","Cost-effectiveness Analysis","Artificial Intelligence (AI)","Cardio Vascular Disease","Cardio-cerebrovascular Disease",[76,77,78,79,80,81,82,83,84],"Atrial fibrillation","Thromboembolic risk","Artificial intelligence","Stroke","Major Adverse Cardiovascular Events","Sex differences","Primary care","Cost-effectiveness analysis","Quality-adjusted life-years","NOT_YET_RECRUITING","2026-02-27",{"date":88,"type":42},"2026-03-02",{"date":90,"type":22},"2026-07-06",{"date":92,"type":22},"2028-12-31",{"name":94,"class":95},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","OTHER",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100621718","do-qt-prolonging-drugs-cause-major-adverse-cardiac-events-in-hospitalized-adults-100621718","NCT07374263","Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?","Do 'Known' QT-prolonging Medications Cause Major Adverse Cardiac Events in Hospitalized Adults? The QTP-MACE Study","QTP-MACE","Inclusion Criteria:\n\n* Adult patients 18 years of age or older\n* Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Outpatient encounters","18 Years",{"count":107,"type":22},990000,"There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability.\n\nIn this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk.\n\nThe objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE.\n\nIn summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.",[110,111,112,113,114,27],"Acquired Long QT","Ventricular Arrhythmias","Torsades de Pointes","Syncope","Medication Safety",[116,117,118,119,120,121],"Medication safety","QT interval prolongation","Long QT syndrome","Ventricular arrhythmia","Torsades de pointes","Major adverse cardiac events","2026-01-24",{"date":124,"type":42},"2026-01-28",{"date":126,"type":42},"2025-02-01",{"date":128,"type":22},"2027-12",{"name":130,"class":95},"St. Joseph's Healthcare Hamilton",2,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":144,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":96},"100618229","steroid-treatment-to-prevent-thoracic-endovascular-aortic-repair-postimplantation-syndrome-100618229","NCT07328906","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome (STOP TEVAR PIS): A Randomized, Double-Blind, Placebo-Controlled Trial","STOP TEVAR PIS","Inclusion Criteria:\n\n* Consecutive patients admitted due to endovascular treatment of aortic dissection type B or thoracoabdominal aortic aneurysm in whom elective, open repair is planned.\n* Patients capable of giving informed consent.\n* Patients who are estimated to be available for long-term follow-up.\n\nExclusion Criteria:\n\n* emergency procedures, the existence of severe renal insufficiency (serum creatinine \\>176 µmol\u002FL or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2), severe liver insufficiency (ALT value more than twice the upper limit or bilirubin levels more than twice the reference values), uncontrolled diabetes mellitus (fasting glycemia above 13.9 mmol\u002FL, i.e. the value glycosylated hemoglobin over 8.5%), existence of active infection or sepsis, autoimmune disease, chronic pain syndromes, proven allergy to methylprednisolone, existence of gastric or duodenal ulcer, immunosuppressive or chemotherapy in the previous three months, active malignant disease, genetic diseases of connective tissue, pregnancy, critical lower limb ischemia, previous endovascular procedure on the aorta, preoperative administration of corticosteroids for any reason, significantly impaired cognitive status or psychiatric illness, acute peri\u002Fmyocarditis, advanced heart failure, as well as voluntary refusal to participate in the study","90 Years",{"count":142,"type":22},174,"INTERVENTIONAL",[145],"NA","Postimplantation syndrome (PIS) is a common and clinically important complication following thoracic endovascular aortic repair (TEVAR). PIS is characterized by a strong systemic inflammatory response to the stent-graft implantation and is manifested by flu-like symptoms, which include fever, increased white blood count, increased levels of acute phase proteins, and fatigue, but without a clear inflammatory and infective cause. Besides, it has been demonstrated that PIS is associated with prolonged hospital stay and increased risk for postoperative complications, including acute kidney injury, postoperative delirium, and increased postoperative pain scores. Recently, there has been increasing evidence that PIS is associated with an increased risk of major adverse cardiac events (MACE) and perioperative myocardial injury. Observational studies suggest that preoperative administration of glucocorticoids may decrease the incidence of PIS after TEVAR and EVAR procedures. However, to date, there are no randomised trials that have investigated whether preoperative administration of glucocorticoids can reduce the incidence of PIS and its associated poorer treatment outcomes following TEVAR. This randomized controlled trial was designed to investigate the effect of glucocorticoid administration on reducing the incidence and improving the outcome of patients who develop PIS after TEVAR.",[148,149,27,150],"Postimplantation Syndrome","Myocardial Injury","Mortality",[152,153,154,155,27,156],"postimplantation syndrome","methylprednisolone","TEVAR","myocardial injury","mortality","2026-01-08",{"date":159,"type":42},"2026-01-12",{"date":161,"type":22},"2026-01",{"date":163,"type":22},"2029-01",{"name":165,"class":95},"University of Belgrade",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":173,"targetDuration":175,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100607570","prospective-observational-cohort-study-on-impact-of-frailty-on-risk-prediction-treatment-strategies-and-short-term-outcomes-in-patients-with-acute-coronary-syndrome-100607570","NCT07190274","Prospective Observational Cohort Study on Impact of Frailty on Risk Prediction, Treatment Strategies, and Short-Term Outcomes in Patients With Acute Coronary Syndrome","Impact of Frailty on Risk Prediction, Treatment Strategies, and Short-Term Outcomes in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n* Elderly: Age ≥65 years .\n* STEMI\u002FNSTEMI (ESC\u002FACC criteria)\n* Presentation \\\u003C24h of symptom onset\n\nExclusion Criteria:\n\n* Terminal illness (life expectancy \\\u003C1 month)\n* Severe dementia precluding assessment\n* Declined consent",{"count":174,"type":22},645,"1 Month","we aim :\n\n* To evaluate how frailty influences acute management decisions (invasive vs conservative strategy) in ACS patients and whether it independently affects short-term outcomes.\n* To determine whether adding frailty assessment to existing ACS risk prediction models improves the prediction of 30-day mortality and major adverse cardiovascular events (MACE) in elderly ACS patients.",[178,179,27,180],"Frailty","ACS (Acute Coronary Syndrome)","GRACE Score",[182,183],"frailty","ACS","2025-09-22",{"date":186,"type":42},"2025-09-24",{"date":188,"type":22},"2025-12-01",{"date":190,"type":22},"2028-06-01",{"name":192,"class":95},"Assiut University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":140,"enrollmentInfo":200,"targetDuration":202,"studyType":23,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100603462","short-term-outcome-in-stemi-patients-undergoing-primary-pci-a-comparative-study-between-rural-and-urban-communities-at-assiut-university-100603462","NCT07136831","\"Short-term Outcome in STEMI Patients Undergoing Primary PCI: A Comparative Study Between Rural and Urban Communities at Assiut University.\"","\"Short-term Outcome of Patients From Rural Versus Urban Communities Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction\"","Inclusion Criteria:\n\n* 1\\. Adults aged ≥18 years. 2. Confirmed diagnosis of ST-segment elevation myocardial infarction (STEMI) based on ECG and cardiac biomarkers.\n\n  3\\. Underwent primary percutaneous coronary intervention (PCI) within the study period.\n\n  4\\. Known and verified residential address classified as rural or urban based on official definitions (e.g., UK or WHO classification).\n\n  5\\. Informed consent obtained\n\nExclusion Criteria:\n\n1. Non-STEMI or unstable angina cases.\n2. Patients who received fibrinolytic therapy instead of PCI.\n3. Transfer from another facility after more than 12 hours of symptom onset.\n4. Patients with previous revascularization (e.g., CABG or PCI within the last 6 months).\n5. Incomplete clinical data or unknown residential location.\n\n   \\-",{"count":201,"type":22},162,"3 Months","this study aims to assess the short-term (3-month) clinical and echocardiographic outcomes of primary PCI among STEMI patients from rural versus urban areas in Upper Egypt. A special focus will be placed on identifying predictors of MACE. The findings may offer valuable insight into optimizing STEMI care pathways and support the development of regional STEMI networks across Egypt.",[27,205],"In STEMI","2025-08-14",{"date":208,"type":42},"2025-08-22",{"date":210,"type":22},"2025-08-15",{"date":212,"type":22},"2026-12-30",{"name":192,"class":95}]